A phase I study of a multi-modal schedule with Corynebacterium parvum.
A Phase I study of an immuno-chemotherapy regime was carried out using C. parvum as an immune-modulator. 14 women were studied. All received doses of C. parvum ranging from 2.5 mg to 21 mg administered in 1 litre of dextrose saline over 4 h. No evidence of tumour enhancement was observed.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008875:Middle Aged; D011425:Propionibacterium acnes